SCHEDULE 13G/A: Perceptive Advisors and Affiliates Maintain 7.5% Stake in Contineum Therapeutics

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have filed an amended Schedule 13G, confirming their beneficial ownership of 7.5% of Contineum Therapeutics, Inc.'s Class A Common Stock.

Summary

• The filing is an Amendment No. 2 to Schedule 13G, reporting beneficial ownership of Class A Common Stock of Contineum Therapeutics, Inc.
• The reporting persons are Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd.
• As of March 31, 2025, the reporting persons collectively beneficially own 1,441,249 shares of Contineum Therapeutics, Inc. Class A Common Stock.
• This ownership represents 7.5% of the outstanding Class A Common Stock.
• The percentage is calculated based on 19,142,377 shares of Common Stock outstanding as of March 14, 2025, as reported in the Issuer's Definitive Proxy Statement on Schedule 14A filed on April 29, 2025.
• Perceptive Life Sciences Master Fund, Ltd. directly holds the shares, while Perceptive Advisors LLC serves as its investment manager, and Joseph Edelman is the managing member of Perceptive Advisors, leading to deemed beneficial ownership for all three.
• All reporting persons hold shared voting and shared dispositive power over the 1,441,249 shares.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Schedule 13G) reporting beneficial ownership, which is inherently neutral in sentiment as it does not contain operational or financial performance updates.

Positives

• The continued beneficial ownership by a significant institutional investor like Perceptive Advisors may signal ongoing confidence in Contineum Therapeutics, Inc.

Negatives

• The document is a standard regulatory filing and does not contain information that would typically be categorized as negative financial or operational news.

Risks

• No specific company-related risks are detailed in this beneficial ownership report, as its primary purpose is to disclose ownership percentages.

Future Outlook

This document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Industry Context

This filing reflects continued institutional investment in the biotechnology and pharmaceutical sector, specifically in Contineum Therapeutics, Inc. by a specialized life sciences investment firm.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership and confirms that the stake is held for passive investment purposes, not for control.

Key Dates

Keywords

Contineum Therapeutics, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, beneficial ownership, Class A Common Stock, institutional investment, SEC filing